Chronic Immune Thrombocytopenia
Hematology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
OctapharmaPanzyga
CASI PharmaceuticalsCID-103
Clinical Trials (2)
Total enrollment: 6 patients across 2 trials
Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Start: Jan 2020Est. completion: May 20246 patients
Phase 4Terminated
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Start: Jan 2025Est. completion: Dec 2026
Phase 1/2Recruiting
Related Jobs in Hematology
Senior Manager – Strategy & Business Transformation
Johnson & Johnson
Mumbai, India
2d ago
MSL Hematología L - Sur
Johnson & Johnson
Sevilla, Spain
2d ago
Délégué Médical LLC/Myélome (H/F) - secteurToulouse
Johnson & Johnson
Issy-les-Moulineaux, France
2d ago
Sr. Director Marketing
Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr
Commercial Strategy Lead – Innovative Gene Therapies (Haematology - BeNeLux)
Vertex Pharmaceuticals
5065 - Vertex Netherlands
5d ago
Key Account Specialist Hematology
Johnson & Johnson
Beirut, Lebanon
5d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 6 patients
2 companies competing in this space